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ABSTRACT 
 
45%-65% of patients with asymptomatic bacteriuria (ASB) are inappropriately 
treated with antimicrobials, leading to an increase in bacterial resistance, cost, 
and adverse health events. Positive urine culture seems to remarkably influence 
antimicrobial use in ASB. The purpose of this project is to answer the question of 
whether among inpatients with positive urine cultures, would modified reporting 
lead to a reduction in inappropriate therapy. 
The study was a randomized, parallel group, superiority trial, comparing two 
different ways to report positive urine cultures. 
In the intention-to-treat analysis, the proportion of appropriate treatment (UTI 
treated plus ASB not treated) in the modified arm was 44/55 (80.0%) vs. 29/55 
(52.7%) in the standard arm, absolute difference= 27.3%, RR=0.42, p=0.002. 
Number needed to report for benefit=3.7. The overall difference in proportion of 
appropriate treatment was produced by a decrease in the number of ASB 
treated. Modified reporting did not increase the occurrence of adverse events. 
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Chapter 1 – INTRODUCTION 
 
1.1 Preamble 
 
The study published by Edward Kass in 1956: "Asymptomatic Infections of 
the Urinary Tract"(1) was the starting point for some fundamental concepts in this 
thesis. Kass was the first to establish the association between bacterial counts 
≥100,000 colony-forming units (CFUs) per ml in urine cultures with patients 
presenting with symptoms of urinary tract infection (UTI). Since then, this number 
has remained the gold standard for the diagnosis of UTI. Additionally, Kass 
described a group of patients who, despite having urine cultures with bacterial 
counts ≥ 100,000CFU/ml, did not present symptoms of UTI; he coined the term 
“asymptomatic bacilluria” for these patients, later known as asymptomatic 
bacteriuria (ASB) or covert bacteriuria. Kass suggested that association between 
asymptomatic bacilluria and pyelonephritis (kidney infection) was not unlikely. 
From that point forward, the influence of ASB on health status and whether 
patients should be treated with antibiotics or not, were sources of controversy. 
 
The cases described in Kass' study, currently known as ASB patients, 
constitute the population affected by the problem the intervention described in 
this thesis aims to improve. At present, they are patients whose urine samples 
are cultured for presenting any sign or symptom mistakenly attributed to a 
potential UTI, e.g., foul-smelling or cloudy urine; or for reasons not related to 
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clinical manifestations, such as routine admission or preoperative testing; and 
subsequently, in nearly half of the cases of these patients with positive urine 
cultures, they are treated with antimicrobials.(2) 
 
ASB is a common clinical finding, particularly among inpatients, the 
elderly, and patients with indwelling urinary catheters.(3) In the 1980s, Dontas et 
al. stated that ASB was associated with a reduction of survival in the elderly.(4) 
Nonetheless, scientific evidence to date has shown that in general, ASB is not 
associated with adverse outcomes. In 2005, Clinical Practice Guidelines (CPGs) 
were published to assist practitioner decisions about appropriate management of 
ASB.(5) CPGs are systematically developed statements based on the best 
available scientific evidence. The aforesaid CPGs for the diagnosis and 
treatment of ASB in adults state that antimicrobial therapy has no role in most 
cases of ASB, and withholding treatment has no impact in mortality and 
morbidity. As discussed further on in this chapter, not only is ASB treatment not 
helpful, it may actually be harmful. 
 
Certainly, patients with ASB are at an increased risk for symptomatic 
UTI;(5) however, the association of ASB with symptomatic UTI is likely caused by 
host factors that facilitate both entities, as opposed to symptomatic UTI being 
caused by ASB.(5) 
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It is not clear why physicians treat ASB with antimicrobials regardless of 
the presence of symptoms, but it may include the fear of consequences of 
ignoring a positive laboratory result.(6) In any case, it represents a lack of success 
in translating evidence into practice. 
 
This Master’s thesis describes a randomized controlled trial to evaluate 
the effect of an intervention conducted in a Microbiology Laboratory, which 
modifies the standard reporting of positive urine cultures, to improve ASB 
management. 
 
1.2 UTI and ASB Definition, Pathophysiology and Epidemiology             
 
UTI and ASB are two separate clinical syndromes, which have in common 
significant bacterial growth from a urine specimen. These syndromes are 
commonly confused, but have very different implications and treatment.   
 
The Infectious Diseases Society of America (IDSA) defines ASB as the 
presence of bacteria in a non-contaminated urine sample collected from a patient 
without clinical manifestations of UTI.(5) In asymptomatic females, the 
determination of ASB requires the isolation of the same microorganism in 2 
successive voided urine samples isolated in amounts ≥ 100,000 CFU/ml.(5) In 
asymptomatic men, one voided urine sample with 1 bacterial species isolated in 
amounts ≥100,000 CFUs/mL; or single catheterized sample with 1 bacterial 
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species isolated in quantitative counts ≥100 CFUs/mL in asymptomatic patients, 
regardless of sex, constitutes the diagnosis of ASB.(5, 7) 
 
Conversely, acute cystitis (UTI affecting the bladder only) causes 
symptoms such as urinary frequency, urgency, dysuria (pain during urination), or 
suprapubic tenderness, with no anatomical anomalies in the genitourinary tract. 
Acute pyelonephritis (UTI affecting the kidney) causes symptoms such as fever, 
flank pain, nausea, vomiting, and rigours.(6) Complicated UTI occurs in patients 
whose genitourinary tract presents a functional or anatomical anomaly, e.g., 
vesicoureteral reflux (backward flow of urine from the bladder to the upper 
urinary tract), or urethral strictures.  
 
The diagnosis of symptomatic UTI in some clinical conditions requires 
different considerations.  Patients with indwelling urethral catheters have difficulty 
in localizing urinary symptoms.(8) therefore typical manifestations of UTI (pain, 
urgency, and dysuria) are uncommon. Clinical assessment of patients with 
limited communication such as advanced dementia or stroke can be challenging. 
In patient with spinal cord lesions, the sensitivity and specificity of symptoms and 
signs are poor.(9) 
 
The microbiology of ASB/UTI mainly comprises gastrointestinal tract 
bacteria, since the mechanism of infection is ascending bacteria, from the bowel 
into the bladder. By far, the most frequently found bacterium is Escherichia coli 
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(75-95%); other causes include Klebsiella spp, Proteus mirabilis, Enterococcus 
and Staphylococcus saprophyticus.(10, 11) 
 
It is considered that bacterial strains capable of triggering a remarkable 
inflammatory response of the urinary bladder epithelium and therefore the 
symptoms of UTI have different, or at least, a higher proportion of virulence 
factors in relation to the strains responsible for ASB.(11, 12) These factors include 
fimbriae, flagella, diverse adhesins, siderophores, toxins, polysaccharide 
coatings, among others, which help the microorganisms in overcoming host 
resistances.(10) Humans count on several urinary tract defenses against bacteria 
colonization such as mechanical flushing of urine flow, urine acidity and 
osmolality, various inhibitors of bacterial adherence, local secretion of cytokines 
and chemokines and bactericidal zinc in prostatic secretions.(13) Risk factors for 
urinary tract colonization are female sex, pregnancy, urological anomalies, 
frequent or recent sexual intercourse, indwelling catheter, spermicide use, 
diabetes, aging, genetic factors and some comorbidities.(10, 11, 14) The initial step 
in the genesis of ASB/UTI corresponds to bacterial colonization of the 
periurethral mucosa; followed by the bacterial ascent to the bladder. In cases of 
bacteria that possess the virulence factors to trigger tissue aggression, they 
cause inflammation of the urinary bladder epithelium (cystitis) and in some cases 
bacterial ascent to the kidney producing pyelonephritis.(11, 13) UTIs with 
involvement of kidneys or prostate are potential sources of bacteremia, and 
Systemic Inflammatory Response Syndrome (SIRS) and sepsis.(15) Bacteremia is 
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the presence of viable bacteria circulating in the blood, while SIRS is a 
widespread inflammatory process associated with infectious and noninfectious 
causes. When a SIRS is concomitant with a known or highly suspected infection, 
it defines a case of sepsis.(16) 
 
UTIs are the most common bacterial infections in general; and the second 
most common in the non-institutionalized elderly.  By the age of 24 years, almost 
one third of all women will experience 1 or more episodes of UTI requiring 
antimicrobials; and close to 50% will have one UTI within their lifetime.(17) Men 
are significantly less likely to experience UTI, accounting for approximately 20% 
of all UTIs.(18) According to The Centers for Disease Control and Prevention 
(CDC), UTIs represent over 12% of infections reported by acute care 
hospitals.(19) 
 
Among healthy women, ASB prevalence varies from approximately 1% of 
preschool girls to almost 20% among women 80 years of age or older living in 
the community.(6) In a study including all preschool girls attending a medical office 
for “well child” checkup, none of whom presenting UTI symptoms, whose urine 
samples were cultured, ASB was found in 0,8% of cases.(20) In another study 
carried out in the geographical catchment area of a  primary health care centre in 
a Swedish municipality, all residents aged ≥ 80 years old, not living in institutions, 
were invited to participate; they found ASB prevalence close to 20% among 
women.(21) ASB is infrequent in healthy young men; a Japanese study found no 
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cases of ASB among more than 1200 men younger than 50 years.(22) Obstructive 
uropathy (structural or functional hindrance of normal urine flow) increases the 
prevalence in older men.(23) Institutionalized patients regularly have significant 
numbers of bacteria in urine, with about 25–50% of females and 15–40% of 
males affected.(6) Urinary catheters enable microorganisms to accumulate, with a 
prevalence of bacteriuria of 9–23% in short-term and 100% in long-term 
catheterization.(6) 
 
1.3 UTI Treatment 
 
Antibiotic treatment is appropriate for UTIs, to prevent bacteria from 
ascending to the kidney or into the bloodstream.   
 
  In 2010, The IDSA and the European Society for Microbiology and 
Infectious Diseases updated the practice guidelines for treatment of UTI. They 
recommended a short-course of antibiotics to treat uncomplicated UTI in 
premenopausal, non-pregnant women. First line agents are: Nitrofurantoin x 5 
days, Trimethoprim-sulfamethoxazole x 3 days (if local resistance rates of 
uropathogens do not exceed 20%) and Fosfomycin trometamol in a single dose. 
Despite the fact that fluoroquinolones are highly efficacious, these practice 
guidelines recommend considering them as alternative (second line) 
antimicrobials for acute cystitis to prevent the ecological adverse effects of 
selection of drug-resistant organisms and infection with multidrug-resistant 
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organisms.(24) According to the European Association of Urology, the prescription 
of short-course therapy (<7 days) is not generally accepted in postmenopausal 
women; and a minimum of 7 days should be prescribed in males.(25) 
 
It is not necessary to request urine cultures in women with clinical 
presentation of uncomplicated UTI; empirical antibiotic treatment may be 
prescribed. The microbiology of these cases is predictable and by the time urine 
culture results are available, a short-course of antibiotic has usually been 
completed. Conversely, in males, pregnant females, and complicated UTIs, 
pretreatment urine culture is recommended, then treatment can be adjusted 
following the results of the culture. It is also appropriate to request urine cultures 
in suspected relapses (infection with the same organism following cure) or 
treatment failure, as well as cases of medication intolerance.(26) 
 
1.4 ASB Treatment 
 
Although the association between bacteriuria and symptomatic urinary 
infection has been reported, treatment of ASB does not diminish the number of 
symptomatic infection among patients with ASB, nor improve outcomes except 
for a temporary microbiological improvement. Hence, in general, screening for 
and treatment of ASB is not recommended in adult population.(5) Only pregnant 
women and patients undergoing traumatic urologic interventions can still be 
considered as candidates to be screened for ASB.(5) 
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There is a large body of evidence supporting the lack of benefit of ASB 
treatment. One study enrolled older female residents of continuing care 
retirement communities who submitted urine for culture. Participants were 
categorized as women with ASB who did not get antibiotic therapy and women 
with ASB who did get antibiotic therapy. Non-bacteriuric women served as 
control. The rate of development of UTI-symptoms for the treated group was 
higher than the rate for the group that was untreated during 6 months following 
treatment.(27) 
 
In another study, 3,578 individuals (more than 90% were hospital visitors), 
aged 20-65, were screened for ASB and 107 cases were detected. Of the 107 
bacteriuric subjects 49 (52%) were treated with nitrofurantoin during one week, 
and 45 (48%) with placebo. 10 (20%) of those treated with nitrofurantoin 
remained bacteriuric after 1 week of treatment, and received a second course of 
therapy with ampicillin. The rest of the subjects, the individuals who had 
responded to nitrofurantoin and the individuals who had been given placebo as 
first treatment, received altogether placebo as second treatment. During one year 
follow-up, 18 (37%) subjects from the treated group and 16 (36%) from the 
placebo group, developed symptomatic UTI. It was concluded that antibiotic 
therapy did not avert the development of symptomatic UTI.(28) 
 
A randomized trial comparing antibiotic therapy with no antibiotic therapy 
in diabetic women with ASB who were followed for up to 36 months, found no 
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significant difference in rates of any symptomatic UTI, pyelonephritis, and 
hospitalization for UTI, as well as in time to a first symptomatic episode.(29) 
 
A systematic review published in 2015 assessed the effectiveness of 
antibiotics for preventing development of symptomatic UTI, and UTI-related 
complications such as urosepsis and pyelonephritis, among adults with ASB. The 
authors did not find differences between antibiotics and no treatment of ASB for 
the development of symptomatic UTI or its complications. The results of the 
meta-analyses comparing antibiotics versus placebo or no treatment showed a 
relative risk (RR) = 1.1 (95% CI= 0.51 to 2.43) of developing symptomatic UTI 
and a RR= 0.80 (95% CI= 0.36 to 1.75) of developing UTI-related 
complications.(30) 
 
Treatment of ASB is commonly associated with the overuse of 
antibiotics.(31) The use of antimicrobials inevitably causes the emergence of 
bacterial resistance, which has followed an uninterrupted steady increase 
historically. Since the advent of penicillin, the constant emergence of new 
antibiotics has lessened the impact of the continuous acquisition of bacterial 
resistance. However, the development of new antibiotics has decreased recently 
in comparison with previous decades;(32) thus decreasing the therapeutic 
alternatives against multidrug-resistant organisms, particularly Gram-negative 
bacteria. Bacterial resistance is a therapeutic challenge that can lead to 
treatment failures, adverse patient outcomes and an economic burden to society. 
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Steps therefore to diminish unnecessary use of antibiotics are required. Lee et 
al.(33) have advocated for several strategies to face the growing issue of bacterial 
resistance which may be summarized in three aspects: (I) creation and 
implementation of Antimicrobial Stewardship Programs; (II) education for 
patients, general public and relevant healthcare professionals; and (III) 
controlling antibiotic usage in veterinary medicine. 
 
There is an association between treatment of ASB with antimicrobials and 
higher rates of bacterial resistance and reinfection, increased care cost, and 
significant collateral damage, including Clostridium difficile–associated diarrhea, 
bacterial vaginosis, and vaginal candidiasis.(7, 29) A systematic review published in 
2014 concluded that among ASB trials that reported higher rates of treatment-
related adverse effects, the number needed to harm (NNH) ranged from 2–10.(6) 
This systematic review included seventeen studies evaluating antimicrobial 
therapy for ASB. With the exception of one, the studies were all conducted 
before the publication of the CPGs for the diagnosis and treatment of ASB in 
2005. The study conducted after 2005 also advocated against treatment for 
ASB.(34) 
 
Clostridium Difficile is the most frequently reported nosocomial pathogen 
in the U.S. and its incidence has been increasing there,(35) as well as in Canada 
and Europe.(36) The U.S. Department of Health and Human Services estimated 
the incidence of Clostridium Difficile infections (CDI) for 2013 at 14.2 per 1000 
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hospital discharges.(37) Some authors have estimated the CDI mortality risk at 
close to 17%, with greater risk for the elderly.(38) In Canada, the increase in 
hospitalization cost of an initial episode of CDI is estimated at $11,930 and 
$15,330 for a recurrent episode.(39) Antibiotic use is the most important precursor 
of CDI. Although almost all antibiotics have been associated with CDI, the most 
frequent are ampicillin, amoxicillin, cephalosporins, clindamycin, and 
fluoroquinolones.(35) A prospective study conducted in 2009 exploring the 
appropriateness of fluoroquinolones use among hospitalized patients found that  
51% of all fluoroquinolone regimens classified as unnecessary were prescribed 
to treat ASB.(40) 
 
It has been observed that repeated antimicrobial courses are associated 
with the fact that bacterial strains isolated from older subjects have an increased 
frequency of resistance relative to younger populations.(8) Treatment for ASB is 
not only ineffective, but an increased risk for resistant infections may prompt 
poorer outcomes in people who contract symptomatic UTI.(6) A study published in 
1998, when uncertainty about how to manage ASB existed, assessed two 
modalities of ofloxacin treatment for ASB. The results of this study are striking, 
not because of the intervention’s ability to eliminate ASB (which we currently 
know is not beneficial), but because of the unfortunate adverse effect of 
promoting bacterial resistance. A group of bacteriuric and asymptomatic 
participants were randomized to receive three possible interventions for three 
months: continuous ofloxacin therapy, pulse ofloxacin therapy, or no treatment. 
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At the end of the study the microbiology of urine cultures classified as 
persistence, relapse or reinfection was assessed (although this was not the 
purpose of the study). They found 55.2% vs. 4.5% of resistance to ofloxacin 
among bacterial isolates from patients treated vs. not treated.(41) 
 
A randomized trial of treatment of ASB among women with recurrent 
urinary tract infections revealed that treatment of ASB is associated with a higher 
rate of symptomatic UTI over one year. Oral antibiotics for treatment of UTI can 
negatively influence the ordinary intestinal microflora, boosting the development 
of antimicrobial-resistant strains, such as resistant potential pathogens that may 
spread within the body and cause severe diseases.(34) 
 
Based on the concept of bacterial interference, ASB may play a beneficial 
role.(6) Bacterial interference makes reference to the antagonism between 
bacterial species during the surface colonization and acquisition of nutrients.(42) 
Zdziarski et al. have proposed that genetic changes such as point mutations, 
DNA rearrangements, and deletions, may prompt some Escherichia coli strains 
to experience a decrease in virulence factors and evolve toward a state of 
adaptation to prolonged in vivo growth in human hosts,(43) which may be 
defensive against superinfection and symptomatic UTI. 
 
The 2005-CPGs specify that pregnant women with ASB are at increased 
risk for unfavourable outcomes such as pyelonephritis and preterm labour, and 
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antibiotic therapy can prevent this situation; thus, screening for ASB is needed 
during pregnancy.(5) However, some controversy has arisen in relation to 
screening and treatment of ASB during pregnancy. Based on the fact that the 
evidence in favour of screening pregnant women is derived from studies 
performed more than 30 years ago, a multicenter, prospective cohort study 
published in 2015, evaluated 16-22 week pregnant women in 13 health facilities 
in the Netherlands. 40 pregnant women with ASB were randomized to receive 
nitrofurantoin, and 45 were randomized to placebo, two times daily for five days. 
163 pregnant women with ASB from the same cohort who decided not to 
participate in the study were followed and served as a control group. It was 
observed that the proportion of preterm labour was not significantly different 
among women with ASB treated, those receiving placebo, and the control group. 
Likewise, there was no significant variation in the incidence of preterm labour 
compared to pregnant women without ASB within the same cohort. ASB did 
show a significant association with pyelonephritis among women with ASB 
treated with placebo or untreated, although with low absolute risk. The author 
concluded that due to the low level of evidence supporting the benefits of ASB 
treatment, coupled with the possibility of side effects caused by antibiotic 
treatment, doubts were raised about the routine screening and treatment of ASB 
among pregnant women.(44) 
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ASB should be treated preceding traumatic urologic interventions with 
mucosal bleeding, since it increases the risk of bacteremia and sepsis in patients 
undergoing such interventions.(5) 
 
Regardless of consistent lack of demonstrable benefit in the majority of 
cases, doctors still treat ASB regularly, with several studies reporting that 45%–
65% of patients get unnecessary antibiotic treatment.(2) A way to positively impact 
public health and patient safety is to promote measures aimed at preventing 
antimicrobial use for the treatment of ASB in patients for which no advantage has 
been shown.(6) 
 
1.5 Interpretation of Positive Urine Culture to Prevent Inappropriate 
Treatment of ASB                           
 
Positive urine culture seems to remarkably influence antimicrobial use in 
ASB treatment. Symptomatic patients are usually treated from the moment they 
seek medical attention, without waiting for the results of the urine culture, while 
asymptomatic patients are usually treated in response to a positive culture.(45) In 
general, urine cultures should only be requested in patients with presence or 
suspicion of UTI related symptoms. Nevertheless, urine cultures are often 
requested because of other reasons not recommended by CPGs including foul-
smelling or cloudy urine, routine admission and follow-up screening, or non-
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specific symptoms of clinical decline such as malaise, behavioural changes, 
lethargy, generalized weakness, falls, or poor appetite.(6) 
 
Although some authors have supported the idea of requesting urine 
cultures routinely prior to non-urologic procedures, such as cardiothoracic, 
orthopedic, and vascular procedures, several recent studies have shown that 
there is no benefit in treating ASB prior to such procedures.(6, 46-48) 
 
Physicians appear to have difficulty avoiding treatment when presented 
with patients’ positive culture results. Various interventions have been proposed 
to reduce inappropriate antibiotic treatment for ASB. A cluster randomized trial of 
an algorithm for diagnosis and treatment of UTI failed to reduce urine culture 
collection rate.(49) 169 residents and staff physicians demonstrated poor 
knowledge of published ASB treatment guidelines, suggesting education may be 
of benefit.(50) Prospective audit and feedback to physicians reduced treatment 
duration, but not treatment initiation decisions, in one study;(51) and reduced 
culture orders and treatment during and after an intervention period in another 
study.(52) An educational intervention reduced inappropriate treatment during the 
intervention period.(53) Audit and educational interventions require considerable 
effort and may not lead to sustainable change. 
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The update of the IDSA and the Society for Healthcare Epidemiology of 
America guidelines published in 2016(54) suggests a more active role by 
microbiology laboratories in antimicrobial stewardship programs. They 
recommend, with low-to-moderate levels of evidence, the use of selective or 
cascade reporting to promote the wise use of antimicrobials. Cascades are 
algorithm-driven reports that contain only a reduced number of tested 
antimicrobial susceptibilities based on availability, local susceptibilities, and 
costs. They further recommend reporting of susceptibility to broader-spectrum 
drugs only when isolates are resistant to drugs in the first "cascade."(55) This type 
of intervention, based on a controlled release of information, aims to influence 
the prescription of antibiotics towards those considered more appropriate 
according to the case. 
 
In a pilot study conducted by Leis and colleagues, non-catheterized 
inpatients with positive urine cultures were reported by the microbiology 
laboratory with a general statement suggesting the physician call the lab if there 
was really clinical suspicion of urinary infection.(45) This provided a barrier to 
access to positive culture results. In the intervention group modified reporting 
reduced inappropriate therapy from 48% to 12%, with no incidence of UTI or 
sepsis among untreated patients. Among 37 positive cultures reported in the 
modified way, only 5 calls were received to the laboratory requesting complete 
culture report. The authors described the design as a controlled before–after 
study. Because the study was not randomized, the ability of this design to control 
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the confounding effect may be compromised. An ideal design would include 
randomization of positive cultures between modified and standard reporting. 
 
1.5 Purpose and Rationale  
 
The purpose of this randomized controlled trial is to address the question 
of whether modified reporting, as compared to standard reporting, of positive 
urine cultures by the Health Sciences microbiology laboratory, would lead to a 
reduction in the rate of inappropriate antibiotic therapy without an increase in 
adverse events.  
 
The Health Sciences microbiology laboratory is part of Eastern Health, 
and in charge of performing all inpatient and outpatient bacteriology testing for 
St. John's, Newfoundland. Eastern Health is the largest Regional Health 
Authority (RHA) of four RHAs in the province of Newfoundland and Labrador, 
serving St. John's and the Eastern region. The city of St. John's has three large 
tertiary care centers; the Health Sciences Centre, St. Clare's Mercy Hospital and 
the Janeway Children's Health and Rehabilitation Centre. 
 
In Eastern Health microbiology laboratories, urine represents half of all 
specimens received, with 30 percent of specimens requiring bacterial 
identification and antibiotic susceptibility testing. In view of the resemblance to a 
study conducted in Ontario,(56) it can be also expected that many of these 
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specimens belong to asymptomatic patients. Preventing ordering of urine 
cultures without clinical indication is an ideal condition, but that is a complicated 
undertaking, requiring changes in long-standing practices and convictions among 
health care providers.(45) Modifying the way urine cultures are reported may be a 
cheaper and easier intervention. Given that positive results from urine cultures 
for ASB are likely to trigger inappropriate prescribing behaviour, modified 
reporting may lead to a reduction in inappropriate antibiotic treatment and its 
complications such as diarrhea due to Clostridium difficile, selection of drug 
resistance bacteria, and cost of treatment. In addition, a demonstration that 
untreated UTI or pyelonephritis are improbable consequences of changing the 
reporting of positive culture results may reassure physicians and nurses 
regarding a more selective procedure in urine collection.  This could reduce 
workload and cost in the microbiology laboratory. The role of David Garcia in this 
project was participating in team meetings discussing the protocol and ethics 
application, coordinating and participating in recruitment and randomization, 
participating in data collection, designing the dataset and entering the data, 
running statistical analyses, and writing the thesis. 
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Chapter 2 – METHOD 
 
 
2.1 Design 
 
The study was a randomized, parallel group, superiority trial, which 
compared two different methods of reporting positive urine cultures, with an 
allocation ratio of 1:1 for two groups of patients. 
 
Urine specimens received for urine culture were inoculated onto blood and 
MacConkey agars, incubated overnight and interpreted quantitatively by the 
regular staff of the Health Sciences microbiology laboratory according to their 
protocol. Eligible positive urine cultures were randomized by three trained 
members of the research team (D. Garcia, S. Boyd, or C. Penney) into standard 
reporting or modified reporting, prior to entry into the laboratory information 
system. Complete results from patients with modified reporting were available to 
clinicians 24 hours a day by telephone, and this was clearly communicated in lieu 
of the standard report. Laboratory staff released complete results by telephone 
and on the electronic chart to physicians who called to request them (Figure 1. 
Intervention Flow). 
 
 
 
21 
 
Figure 1. Intervention Flow 
 
 
 
2.2 Participants: 
 
Between January 3, 2017, and March 27th, 2017, all consecutive positive 
urine cultures processed by the microbiology laboratory were assessed. Urine 
cultures were considered positive if a bacterium was isolated in amounts greater 
than or equal to 100,000 CFUs/ml. Specimens included were collected only from 
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inpatients admitted to one of the two tertiary adult care academic teaching 
hospitals in St John’s: Health Sciences Centre and St. Clare's Mercy Hospital. 
Eligibility was assessed by review of medical records by study personnel (D. 
Garcia, S. Boyd, or C. Penney). In cases whose medical records were not explicit 
enough to ensure eligibility of the participant, e.g. no clear method of sample 
collection, the nurse in charge of the patient was called from the laboratory to 
complete the information (without discussing the research project). 
 
 Inclusion criteria were: 
• Inpatients admitted to one of the two included acute care facilities. 
 
 Exclusion criteria were: 
• Pregnancy 
• Receiving antibiotics at the time of collection 
• Absolute neutrophil count < 1x109/liter 
• Admitted to the Intensive Care Unit 
• Indwelling catheter 
• Age less than 18 years 
 
Pregnant women were excluded because ASB treatment is appropriate for 
them. Patients receiving antibiotics at time of collection were excluded to simplify 
the assessment of physician’s prescribing behaviour after the report of urine 
cultures. Neutropenic patients were excluded because there is still no clear 
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consensus on whether or not they must be treated.(5, 57) ICU patients were 
excluded because they are critically ill patients who habitually have indwelling 
catheters, and a large portion of them have endotracheal tubes or alterations in 
level of consciousness, which makes it difficult to assess UTI manifestations. The 
definition of UTI in patients with indwelling catheters includes criteria different 
than those used in this project, therefore they also were excluded.(58) 
 
2.3 Intervention 
 
Included patients were randomized equally into standard or modified 
report arms. The standard report (control arm) included bacterial count, bacterial 
identification and susceptibility information including drug dosage and cost, in the 
regular format, while the modified report (intervention arm) withheld the standard 
report information, and expressed verbatim: “This POSITIVE urine culture may 
represent asymptomatic bacteriuria or urinary tract infection. If urinary tract 
infection is suspected clinically, please call the microbiology laboratory at xxx-
xxxx between 0900 to2300, or the microbiology technologist on-call at xxx-xxxx 
at night, for identification and susceptibility results.” 
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2.4 Outcomes 
 
The primary outcome was the proportion of inappropriate antibiotic 
treatment. Inappropriate treatment was defined as treated ASB or untreated UTI, 
and appropriate treatment was defined as untreated ASB or treated UTI.  
 
After randomization, medical records of included cases were assessed by 
a study physician (P. Daley or R. Inayatullah)  for a clinical diagnosis of UTI or 
ASB, using criteria from the CDC for non-catheterized urine specimens.(19) These 
criteria state that diagnosis of UTI requires the presence of at least one of the 
following signs or symptoms: fever >38°C, suprapubic tenderness, costovertebral 
angle pain or tenderness, urinary frequency, urinary urgency, or dysuria. 
Conversely, ASB was defined as the absence of any of these signs or symptoms. 
Reassessments of each case were scheduled at 72 hours and at seven days 
after randomization to collect data on treatment decisions (time of prescription, 
drug given, and indication), and adverse events for safety assessment. ASB was 
considered treated when an antimicrobial was prescribed in patients who did not 
present any other condition that required the usage of the antibiotic. Presence of 
any of the CDC UTI criteria in a patient with no antimicrobial treatment was 
considered as UTI untreated. 
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As measures of secondary efficacy outcomes, the study team recorded 
the number of calls from physicians requesting access to complete reports, and 
calculated the cost saving from reduction in antimicrobial treatment. 
 
As safety outcomes, we determined bacteremia rate, number of deaths 
and adverse events at 72 hours and at 7 days. As adverse events at 72 hours, 
we searched for evidence of SIRS, such as changes in vital signs (body 
temperature >38.3oC or <36oC, pulse > 90/min, and respirations > 20/min) and 
mental status, abnormal white blood cells count (>12,000 or < 4,000 per 
microliter of blood), positive fluid balance (fluid intake higher than output), and 
hyperglycemia (fasting plasma glucose ≥7.0 mmol/L). At seven days, any other 
new symptoms were recorded. 
 
Investigators did not speak with attending physicians. If patients were 
discharged during the follow-up period, health records were reviewed, and 
primary care doctors were telephoned by P. Daley to collect information about 
adverse events.  
 
In cases when doctors asked for standard reporting after receiving a 
modified report, the patient was analyzed as randomized and kept in follow-up. 
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2.5 Sample Size 
 
In agreement with the report of Leis et al,(45) the expected rate of 
inappropriate treatment was 45% in the standard reporting arm and 15% in the 
modified reporting arm. Power analysis for chi-squared test of proportions, with a 
two-sided 5% significance level and type 2 error of 20%, suggested a total 
sample size of approximately 90 patients. Allowing for attrition/losses to follow-
up, 110 eligible consecutive in-patient samples were included in the study. This 
calculation was based on the number of urine samples, disregarding the number 
of health personnel involved in the care of these patients; therefore it is possible 
that a single individual requested more than one of the included samples, and 
some physicians could have been exposed to the intervention more than once.  
 
2.6 Interim Analysis and Stopping Rules 
 
There was no predefined stopping rule. The study was stopped once the 
planned sample size was achieved. 
 
2.7 Randomization 
 
A non-member of the research team used randomization software 
(Research Randomizer 4.0) to randomize the sequence numbers from 1 to 110. 
The even numbers were used to generate cards assigning participants to the 
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standard arm and the odd numbers to the modified arm. Cards containing the 
participant allocation were placed in serially numbered, sealed, opaque 
envelopes. After a specimen was determined as eligible by an investigator, it was 
included in the study and the corresponding envelope was opened. The 
envelopes were opened strictly as numbered. 
 
2.8 Blinding 
 
To comply with ethics requirements, a general notice was sent to all 
inpatient physicians informing them about the study prior to recruitment. Since 
investigators in charge of outcome assessment had access to urine culture 
reports, they were not blinded to randomization arm. Patients were not aware of 
the study. 
 
2.9 Statistical Analysis 
 
The proportion of appropriate treatment in each arm was compared using 
two-sided Pearson chi squared test (SPSS 23.0, IBM, USA) in an Intention-to-
treat (ITT) analysis; thus, all 110 randomized cases were included and analyzed 
as originally allocated. A Per-protocol (PP) analysis was also conducted, in which 
only cases that fulfilled the protocol in terms of eligibility were analyzed, and 
inappropriately included samples were excluded. Additionally, a subgroup 
analysis by diagnosis (UTI/ASB) was conducted to determine the impact of each 
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subgroup on outcomes. In order to estimate the difference in antibiotic cost 
between arms, the total cost of antibiotics to treat UTI was calculated in each 
included case, all randomized patients were included, untreated UTI and 
untreated ASB were considered as cost = 0. We determined median cost and 
mean cost per episode in each arm. Since the variable “cost” was not normally 
distributed, a Mann Whitney U test was used to compare the medians between 
groups. 
 
2.10 Ethics 
 
The protocol was approved by the Provincial Health Research Ethics Board on 
June 30, 2016 (reference #2016.157). Physician consent requirement was 
waived because the intervention incurred no more than minimal risk to 
participants, it was unlikely that it affected participants’ well-being, and pursuing 
doctors’ consent would have likely influenced their behavior, however, a letter 
was sent to all inpatients’ physicians advising them about the study prior to 
recruitment, and a debrief meeting offering a chance to withdraw participation 
was provided. Patient consent requirement was waived because physicians were 
the research subjects. Debrief letters were sent to patients, and they were also 
offered the opportunity to be removed from the study. 
 
 
 
29 
 
Chapter 3 – RESULTS 
 
3.1 Participant Flow 
Between January 3rd, 2017, and March 27th, 2017, 286 sequential 
positive urine cultures were surveyed. After determining they did not meet the 
inclusion criteria, 176 specimens were excluded (see Figure 2. Participant Flow). 
The total sample size comprised 110 urine cultures that were randomized and 
included in the ITT analysis; 55 were randomized to standard reporting and 55 
were randomized to modified reporting. Four cases randomized to standard 
reporting (one collected from indwelling catheter, one duplicate, one on 
antibiotics, one culture negative) and two cases randomized to modified reporting 
(two duplicate) did not follow protocol and were excluded from the PP analysis. 
The last patient follow-up period ended on April 3rd, 2017. 
 
3.2 Baseline Demographics 
The two groups were comparable in demographics (see Table 1), with 
similar mean age and percentage females. However, as a result of randomization 
a slightly higher percentage of UTIs were obtained in the modified reporting arm: 
20/55 (36.3%) vs. 14/55 (25.4%) in the standard reporting arm. Of all positive 
urine cultures, 69.1% (76/110) were defined as ASB, not UTI. 
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Figure 2. Participant Flow 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
    
 
 
 
 
 
 
 
 
 
Assessed for eligibility (n=286) 
Excluded (n =176) 
-Indwelling urinary catheter (n=93) 
-Receiving antibiotics (n=25) 
-Admitted to long term care (n=25) 
-Children (n=9) 
-Duplicate (n=8) 
-Admitted to peripheral hospital (n=6) 
-Admitted to ICU (n=4) 
-Neutrophil Count <1x103/l (n=3) 
-Died before randomization (n=2) 
-Pregnant (n=1) 
 
 
 
Randomized (n =110) 
Allocated to standard reporting (n =55) 
 
-Received standard report (ITT) (n =55) 
 
-Followed Protocol (PP) (n=51/55) 
• Duplicate collection (n=1) 
• Indwelling catheter (n=1) 
• Receiving antibiotics (n=1) 
• Negative Culture (n=1) 
 
 
…) 
(give reasons) 
 
 
Allocated to modified reporting (n=55) 
 
-Received modified report (ITT) (n=55) 
 
-Followed Protocol (PP) (n=53/55) 
• Duplicate collection (n=2) 
 
 
Completed 72 hours follow-up (n = 54/55)  
• Discharged during follow-up (n=1) 
 
Completed 7 day follow-up (n = 53/55)  
• Died during follow-up (n=1) 
 
 
Completed 72 hours follow-up (n = 55/55)  
 
 
Completed 7 day follow-up (n = 53/55)  
• Died during follow-up (n=2) 
 
 
Analyzed 
 
Efficacy ITT (55/55), PP (51/55) 
 
Safety 72 hours (54/55), 7 day (53/55) 
 
 
Analyzed 
 
Efficacy ITT (55/55), PP (53/55) 
 
Safety 72 hours (55/55), 7 day 
(53/55) 
 
Enrollment 
Allocation 
Follow-up 
Analysis 
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Table 1. Patient Demographics 
 
 
Standard Reporting (n=55) 
 
Modified Reporting (n=55) 
 
Age (mean +/- SD) 68.6 +/- 16.0 years 67.7 +/- 16.3 years 
Females 36/55 (64.5%) 35/55 (63.6%) 
Urinary tract infection 
(UTI) 
14/55 (25.5%) 20/55 (36.4%) 
Asymptomatic bacteriuria 
(ASB) 
41/55 (74.5%) 35/55 (63.6%) 
 
 
3.3 Efficacy 
 
The primary outcome of appropriate treatment (UTI treated plus ASB not 
treated) was very similar in both the ITT and PP analysis; namely, it was 
significantly higher in the modified arm than in the standard arm (Table 2. 
Proportion of patients receiving appropriate treatment). In the ITT analysis, the 
proportion of appropriate treatment in the modified arm was 44/55 (80.0%) vs. 
29/55 (52.7%) in the standard arm, absolute difference= 27.3%, RR=0.42 (95% 
CI= 0.23 to 0.77), p=0.002, Number needed to report for benefit=3.7. Likewise, 
The PP analysis showed appropriate treatment in 42/53 (79.2%) cases vs. 26/51 
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(51.0%), absolute difference= 28.2%, RR=0.42 (95% CI= 0.23 to 0.77), p=0.002, 
Number needed to report for benefit=3.5. 
 
Table 2.Proportion of patients receiving appropriate treatment 
 
 Report  
Absolute Risk 
Reduction 
 
 
Relative Risk 
(95% CI) Standard Modified 
ITT population 29/55 (52.7%)  44/55 (80%) 27.3% 0.42 (0.23, 0.77) 
PP population 26/51 (51%) 42/53 (79.2%) 28.2% 0.42 (0.23, 0.77) 
 
 
In the subgroup analysis, it was observed that the overall difference in 
proportion of appropriate treatment was mainly caused by a change in the 
proportion of treatment of ASB, not in the proportion of treatment of UTI (see 
Table 3). In the ITT analysis, there was a significant increase of ASB not treated 
among patients randomized to the modified reporting arm in comparison to 
patients with standard report, 26/35 (74,3%) vs. 17/41 (41.5%) respectively; 
absolute difference= 32.8%, RR=0.44 (p=0.004). It is worth noting that the 
number of UTI untreated was the same in both arms (2 cases in each arm). In 
the PP analysis the rate of ASB not treated increased from 15/38 (39.5%) in the 
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standard arm to 25/34 (73.5%) in the modified arm; absolute difference= 34%, 
RR=0.44 (p=0.004).  
 
Table3. Subgroup analysis according to diagnosis. 
Proportion of patients receiving appropriate treatment 
 
 Report  
Absolute Risk 
Reduction 
 
Relative Risk 
(95% CI) Standard Modified 
ITT population 
ITU (n=34) 12/14 (85.7%) 18/20 (90%) 4.3% 0.7 (0.11,4.4) 
ASB (n=76) 17/41 (41.5%) 26/35 (74.3%) 32.8% 0.44 (0.24,0.82) 
PP population 
ITU (n=32) 11/13 (84.6%) 17/19 (89.5%) 4.9% 0.68 (0.11,4.3) 
ASB (n=72) 15/38 (39.5%) 25/34 (73.5%) 34% 0.44 (0.24,0.81) 
 
 
Among 53 specimens in the PP analysis randomized to modified 
reporting, in fourteen cases (26.4%), the attending physician called the laboratory 
to request the complete report.  
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3.4 Safety 
There were three bacteremias observed during the study, two in the 
standard reporting arm (both treated UTI) and one in the modified reporting arm 
(treated UTI). All bacteremias occurred on blood cultures collected at the time of 
admission to hospital; i.e. before inclusion of cases in the study. Therefore, none 
were considered related to the study intervention. The bacteremic patient 
randomized to modified reporting presented neither features of SIRS nor any 
other new symptom during the follow-up. See Table 4. Bacteremias. There were 
three deaths observed, one in the standard reporting arm (untreated ASB) and 
two in the modified reporting arm (one untreated ASB and one treated UTI). 
None were considered related to the study intervention. See Table 5. Deaths. 
The bacterium isolated from urine culture of the patient who died with UTI and 
modified report (study number 81) was Escherichia coli. The patient was treated 
with ceftriaxone, which had adequate action against this bacterium according to 
susceptibility information. 
There were complete data available for 72-hour safety assessment on 
109/110 patients (one discharged during follow-up). There were complete data 
available for seven-day safety assessment on 107/110 patients (three deaths 
during follow-up). See Figure 2. Participant Flow. There was not any noticeable 
trend in occurrence of adverse events during the follow-up period comparing 
standard and modified reporting. At 72 hours, features of SIRS were uncommon 
in both arms. See Table 6. Adverse Events at 72 Hours.  At seven days, new 
symptoms were observed in both arms; most of them were unrelated to UTI; 
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although dysuria, chills, delirium and nausea were seldom observed. See Table 
7. Adverse Events at Seven Days. 
 
3.5 Cost 
 
The mean cost of antibiotic treatment given per episode of UTI/ASB was 
$35.78 +/- $109.77 (Median= $3.64) in the standard reporting arm, compared to 
$19.84+/- 64.88 (Median= $1.1) in the modified reporting arm (mean cost savings 
= $14.94/episode), p=0.231.  
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Table 4. Bacteremias 
Study Number 40 44 56 
Study arm Modified Standard Standard 
Age 79 81 61 
Gender Male Female Female 
Reason for 
Admission 
Urinary Tract 
Infection 
Urinary Tract 
Infection 
Diverticulitis 
Comorbidities Bladder 
carcinoma 
Psoriatic arthritis, 
Spinal stenosis, 
Pulmonary embolus 
Alcoholism 
 
Reason for Urine 
Culture Collection Fever 
 
Fever Fever 
Urine Culture Date 
and Result February 1: E.coli February 3: E.coli February 14: E.coli 
 
Reason for Blood 
Culture Collection 
Fever Fever 
 
Fever 
Blood Culture Date 
and Result February 1: E.coli February 3: E.coli February 14: E.coli 
Study Diagnosis UTI treated UTI treated UTI treated 
Antimicrobial 
Therapy 
Ceftriaxone IV, 
Ciprofloxacin IV, 
Vancomycin IV 
Piperacillin/Tazobac
tam IV 
Piperacillin/Tazobac
tam IV 
Presumed Cause of 
Bacteremia UTI UTI Diverticulitis 
Bacteremia Related 
to Intervention No No No 
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Table 5. Deaths 
Study Number 37 67 81 
Study arm Standard Modified Modified 
Age 70 67 86 
Gender Male Male Male 
Reason for 
Admission 
Hip Fracture, 
Rhabdomyolysis  
Bowel Obstruction Urinary Tract 
Infection 
Comorbidities Cirrhosis 
Metastatic Bowel 
Sarcoma, 
Atrial Fibrillation 
Aortic Stenosis, 
Congestive Heart 
Failure 
Reason for Urine 
Culture Collection Unknown 
 
Incontinence Septic Shock 
 
Urine Culture Date 
and Result 
January 
29:E.faecalis 
 
February 23:           
E. faecalis 
March 4:E. coli 
Blood Culture Date 
and Result None None March 4: Negative 
Study Diagnosis ASB untreated ASB untreated UTI treated 
Study Day of Death 3 6 2 
Antimicrobial 
Therapy 
 
Metronidazole IV  None Ceftriaxone IV 
Presumed Cause of 
Death Renal failure Sarcoma UTI 
Bacteremia Related 
to Intervention No No No 
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Table 6. Adverse Events at 72 Hours 
 
 Modified Reporting Standard Reporting 
Tachycardia 4 5 
Abnormal Temperature 0 0 
Hyperglycemia 0 0 
Edema 1 1 
Elevated White Blood Cell Count 0 3 
Altered Mental Status 2 5 
Tachypnea  0 3 
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Table 7. Adverse Events at Seven Days 
 
 Modified Reporting 
 
Standard Reporting 
 Surgical Site Infection 1 0 
Delirium 0 1 
Diarrhea 0 1 
Chills 0 1 
Increased Wound Drainage 1 0 
Diaphoresis 1 0 
Sputum 1 0 
Trigeminal Neuralgia 1 0 
Headache and Abdominal 
Pain 
0 1 
Dysuria 1 0 
Nausea 0 1 
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Chapter 4   – DISCUSSION 
 
The modification in the report of positive urine cultures applied in this 
study is based on the proof of concept study conducted by Leis. In order to 
diminish potential source of bias to the maximum, we conducted a randomized 
trial design and proved the efficacy of this laboratory intervention to improve 
antibiotic stewardship regarding UTI / ASB. 
 
The significant reduction in treatment inappropriateness of patients with 
positive urine cultures who received modified reporting is produced by a 
decrease in the number of ASB treated. Treated and untreated UTI numbers 
remained technically the same between the study groups. The subgroup analysis 
showed the intervention did not affect UTI cases management, it presented a 
relative risk of inappropriate treatment of UTI within a wide 95% confidence 
interval (0.11-4.4); thus modified reporting did not cause significant difference in 
the risk of inappropriate treatment of UTIs. 
 
Regarding safety, the intervention was not associated with harm to 
patients whose samples were included. The occurrence of adverse events was 
the same in both arms. None of the outcomes related to safety (bacteremia, 
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death, features of SIRS, and new symptoms at 7 days) presented a difference in 
occurrence greater than one between the groups. 
 
The intervention did not result in cases with untreated UTI. This statement 
is based on the fact that the number of UTIs untreated was the same in both 
arms. We observed four cases of symptomatic patients who did not receive 
antibiotic therapy throughout the study, two of them received modified reporting 
and two received standard reporting. 
 
Modified reporting might represent a potential risk of favouring empirical 
treatment, which in turn could favour the use of inappropriate antibiotics in terms 
of microbial susceptibility. We did not record if the antibiotics prescribed to 
patients with UTI-treated in the modified reporting arm showed adequate action 
according to the susceptibility report; however, the fact that the progress of 
patients in terms of occurrence of adverse events was very similar between the 
two study arms, makes it very unlikely that the intervention resulted in the 
prescription of antibiotics without activity against any of the bacteria within 
patients with UTI. It is, however, possible that this intervention, in areas or 
countries with higher rates of bacterial resistance, would lead to a higher risk of 
adverse events. 
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Several reasons have been reported as rationale to collect inappropriate 
urines samples. Daley et al. in a study conducted on residents of long-term care 
facilities located in Newfoundland and Labrador, Canada, found that nurses 
requested urine cultures due to changes in patient behaviour, change in mental 
status, change in colour or character of urine, previous UTI, or patient request, 
among others(59). Leis et al. studying inpatients in two teaching hospitals in 
Ontario, Canada, mentioned as reasons to inappropriately order urine cultures: 
confusion, unexplained leukocytosis, previous history of UTI, abnormal smell or 
colour of urine, recent catheterization, urinary retention, weakness or dizziness, 
and dysglycemia.(56) These reasons lead physicians to face positive culture 
results coming from patients with no clinical indication to be either tested or 
treated, and possibly not requested by them but by nursing staff. The intervention 
described in this study demonstrated ability to reduce these events and therefore 
the reflexive prescription of antibiotics. The modified report advises the doctor 
that the culture is positive and recommends contact with the laboratory in case of 
clinical suspicion of UTI to access identification and bacterial susceptibility. It is 
possible that this kind of report may increase mindfulness regarding the 
appropriateness of antimicrobial therapy. The doctor can choose to reassess 
patient history, contact the laboratory for additional results, or treat empirically. 
The majority (69%) of cultures in our study were regarded as ASB. This 
indicates the potential extent of the problem. 
The reduction of unnecessary antibiotic usage, in addition to obvious 
savings in pharmacy expenses, leads to other potential outcomes as important or 
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even more important, such as avoiding bacterial resistance, Clostridium Difficile-
associated diarrhea, bacterial vaginosis and vulvovaginal candidiasis. 
We relied on data collected directly from medical records and data 
provided by nursing staff to make clinical diagnoses of ASB vs. UTI among 
patients whose samples were included. In cases where medical records may not 
have been thoroughly prepared or in cases of patients who may have had some 
difficulty in communicating the presence of urinary symptoms, our diagnosis 
could have been biased towards ASB. Moreover, it is possible that nurses may 
have misinterpreted some symptoms and reported such patients as having UTI 
symptoms. However, given that we used randomization, this source of bias 
should be balanced between both groups. 
Although ethics required circulating an email to inform physicians about 
the study existence before starting the recruitment, making treating-doctors’ 
blinding impossible, the impact that such email might have had on our results 
does not seem to change the applicability of this intervention in a "real world" 
situation. In fact, in a hypothetical scenario of a larger scale application of this 
intervention, it may be expected that the addition of some educational 
intervention to make physicians aware about correct indications of urine cultures 
and management of patients with ASB might produce even more favorable 
results.(60) 
The application of this modified reporting in a "real world" situation would 
suppose an increase on microbiology staff workload. For doctors, it would 
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represent some loss in their autonomy, and time consumption when contacting 
the laboratory is needed.  
 
Another lab step that could also be suitable to be intervened is the 
acceptance of urine specimens to be cultured; by establishing as a requirement 
the confirmation that the specimen really comes from a patient with indication to 
be tested. In order to achieve this, an effective communication between the 
laboratory and the collection site would have to be set up. This would be an 
intuitive approach, since inappropriate test requesting is a common issue.(56) 
Rejecting non-indicated urine cultures would result in a considerable decrease of 
workload. Modifying request forms have been proposed to improve the 
appropriateness of test submissions.(61, 62) The use of requests forms asking 
providers to indicate the reason for urine culture, coupled with the availability to 
telephone call from the microbiology laboratory in cases when the information on 
the form is not sufficient, might be an approach to be considered. However, this 
intervention would require extra effort to contact the test requestor, who might 
indeed be unavailable, and therefore it could require third parties’ involvement to 
obtain the clinical information. Additionally, this intervention, unlike modifying 
reporting, might result in the rejection of samples with legitimate reasons to be 
tested. On the other hand, using the Health Sciences Microbiology Laboratory as 
an example, the fact that out of the approximately 130 daily urine cultures, 70% 
are negative, and over-half of positive cultures may represent ASB, in addition to 
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a cost of about $15 per urine culture,(63) makes a strong case that any effort to 
identify and reject unnecessary samples may be financially beneficial. 
Several limitations of this study must be mentioned. We did not measure 
the variable “time to symptoms resolution”; therefore we are not able to ensure 
that the intervention did not delay the relief of urinary symptoms among patients 
with UTI. The expected frequency of ASB cases is much higher than the 
expected frequency of urosepsis in the study population; hence, our sample size 
is underpowered to rule out a clinically significant difference (if any) in the 
occurrence of SIRS symptoms between a group with standard reporting and one 
with modified reporting. Follow up in larger populations would be required to state 
unequivocally that this difference does not exist. Lastly, blinding of outcome 
assessment could not be ensured, so determination of outcomes may have been 
biased towards a beneficial effect of the intervention. 
There is no reason to think that our results could not be generalized to 
some populations that were not included in our recruitment, such as: children 
older than two years old, residents of long-term care facilities, carriers of 
indwelling catheters, and outpatients. Thus, future research could expand the 
application of this intervention to include those populations. Demonstration of 
safety and efficacy of modified reporting in those populations is an important step 
forward in its implementation by increasing its scope of application and facilitating 
the screening of samples. 
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There are some changes and additions that can be considered in future 
research to improve this study design: (i) blinding of outcome assessment, (ii) 
prolongation of follow-up period, (iii) measurement of some other outcomes such 
as time to symptoms resolution, and the emergence of resistant strains after 
antimicrobial treatment, (iv) inclusion of a qualitative component to capture the 
experiences and perspectives of physicians. 
 
In conclusion, this study has demonstrated through a randomized 
controlled design that modified urine culture reporting is associated with a 
significant reduction in inappropriate treatment, without an increase in adverse 
events. Our results support the idea that the microbiology laboratory can have a 
more active role in improving adequacy of treatment given to patients with ASB / 
ITU by applying a simple and sustainable intervention such as modified reporting. 
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